In a report issued on May 5, Andrew Berens from SVB Securities assigned a Buy rating to AVEO Pharma (AVEO – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $4.31.
According to TipRanks.com, Berens is ranked 0 out of 5 stars with an average return of -13.5% and a 36.1% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics.
Currently, the analyst consensus on AVEO Pharma is a Strong Buy with an average price target of $15.75, representing a 246.2% upside. In a report issued on May 5, Robert W. Baird also maintained a Buy rating on the stock with a $17.00 price target.
The company has a one-year high of $7.59 and a one-year low of $3.06. Currently, AVEO Pharma has an average volume of 285K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
Read More on AVEO:
- SVB Securities Thinks Bio-Techne’s Stock is Going to Recover
- Agilon Health (AGL) Receives a Buy from SVB Securities
- Editas Medicine (EDIT) Gets a Hold Rating from SVB Securities
- SVB Securities Thinks Deciphera Pharmaceuticals’ Stock is Going to Recover
- SVB Securities Thinks Natera’s Stock is Going to Recover